SCHEDULE: Indivior Pharmaceuticals: Madison Avenue Group Discloses Stake

Madison Avenue International LP and affiliated entities report beneficial ownership of 4,315,162 shares, representing 3.5% of Indivior Pharmaceuticals' common stock as of March 31, 2026.

Summary

• Madison Avenue International LP, along with Madison Avenue Partners, LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC, and Eli Samaha, have collectively reported beneficial ownership of 4,315,162 shares of Indivior Pharmaceuticals, Inc. common stock.
• This holding represents approximately 3.5% of the company's outstanding common stock as of March 31, 2026.
• The filing is an amendment to a Schedule 13G, indicating a passive investment stake.
• The reporting persons do not hold shares for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of passive ownership and does not inherently signal positive or negative developments for the company, but rather an investor's position.

Positives

• Significant passive stake reported, indicating investor confidence or interest in Indivior Pharmaceuticals.
• The reporting persons collectively hold a substantial block of shares (3.5%) which could be seen as a positive signal by the market.

Risks

• While the filing states the securities are not held for the purpose of influencing control, any significant shift in this passive stake could be perceived negatively by the market.
• The concentration of ownership among a few entities could lead to coordinated actions that might impact share price, though the filing explicitly denies intent to influence control.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of beneficial ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment funds accumulating significant stakes in publicly traded companies. This filing indicates Madison Avenue International LP and its affiliates are passive investors in Indivior Pharmaceuticals, not seeking to control the company.

Stakeholder Impact

• Shareholders: The filing provides transparency on a significant passive ownership stake, which can influence market perception.
• Management: The filing confirms that the reporting persons do not intend to influence control, which may provide some reassurance to current management.
• Creditors: No direct impact is indicated.

Next Steps

• The reporting persons will continue to monitor their investment in Indivior Pharmaceuticals.
• Future filings will be made if there are material changes in beneficial ownership or intent.

Key Dates

Keywords

Indivior Pharmaceuticals, Schedule 13G, Madison Avenue International LP, Beneficial Ownership, Common Stock, SEC Filing, Investment, Passive Stake